Pommery Nicole, Hénichart Jean-Pierre
Institut de Chimie Pharmaceutique Albert Lespagnol, Université de Lille 2, Lille, France.
Mini Rev Med Chem. 2005 Dec;5(12):1125-32. doi: 10.2174/138955705774933356.
This review presents some therapeutic interventions actually considered in prostate cancer therapy to compensate constitutive activation of the PI3K/Akt signalling pathway induced, particularly, by mutations of PTEN gene. Special emphasis is placed on applicability of EGF-R tyrosine kinase, COX-2, PDK-1, mTOR and farnesyltransferase inhibitors.
本综述介绍了一些在前列腺癌治疗中实际考虑的治疗干预措施，以补偿特别是由PTEN基因突变诱导的PI3K/Akt信号通路的组成性激活。特别强调了表皮生长因子受体（EGF-R）酪氨酸激酶、环氧合酶-2（COX-2）、丙酮酸脱氢酶激酶-1（PDK-1）、哺乳动物雷帕霉素靶蛋白（mTOR）和法尼基转移酶抑制剂的适用性。
